Riluzole
Active ingredient: Riluzole
In short: Riluzole tablets is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
What is Riluzole used for?
Riluzole tablets is indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Riluzole dosage
The recommended dosage for riluzole tablets is 50 mg taken orally twice daily. Riluzole tablets should be taken at least 1 hour before or 2 hours after a meal .
Measure serum aminotransferases before and during treatment with riluzole tablets .
How to take Riluzole — instructions & advice from the label
Advise patients to inform their healthcare provider if they experience:
Yellowing of the whites of the eyes
Fever
Respiratory symptoms—for example, dry cough and difficult or labored breathing
Manufactured for: Quinn Pharmaceuticals, Boca Raton, FL
Toll Free Number: 954-755-0502
Manufactured by: Standard Chem. & Pharm. Co., Ltd., No. 154 Kaiyuan Road, Sinying District, Tainan City, Taiwan (TWN)
Warnings & precautions
Do not take this medicine if: Riluzole tablets is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components (anaphylaxis has occurred) .
5.1 Hepatic Injury
5.2 Neutropenia
5.3 Interstitial Lung Disease
Cases of drug-induced liver injury, some of which were fatal, have been reported in patients taking riluzole tablets. Asymptomatic elevations of hepatic transaminases have also been reported, and in some patients have recurred upon rechallenge with riluzole tablets.
In clinical studies, the incidence of elevations in hepatic transaminases was greater in riluzole-treated patients than placebo-treated patients. The incidence of elevations of ALT above 5 times the upper limit of normal (ULN) was 2% in
riluzole -treated patients. Maximum increases in ALT occurred within 3 months after starting riluzole tablets. About 50% and 8% of riluzole-treated patients in pooled Studies 1 and 2, had at least one elevated ALT level above ULN and
above 3 times ULN, respectively .
Monitor patients for signs and symptoms of hepatic injury, every month for the first 3 months of treatment, and periodically thereafter. The use of riluzole tablets is not recommended if patients develop hepatic transaminases levels greater than 5 times the ULN. Discontinue riluzole tablets if there is evidence of liver dysfunction (e.g., elevated bilirubin).
Cases of severe neutropenia (absolute neutrophil count less than 500 per mm3) within the first 2 months of riluzole treatment have been reported. Advise patients to report febrile illnesses.
Interstitial lung disease, including hypersensitivity pneumonitis, has occurred in patients taking riluzole tablets. Discontinue riluzole tablets immediately if interstitial lung disease develops.
Riluzole side effects
The following adverse reactions are described below and elsewhere in the labeling:
Hepatic Injury
Neutropenia
Interstitial lung disease
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Controlled Clinical Trials
In the placebo-controlled clinical trials in patients with ALS (Study 1 and 2), a total of 313 patients received riluzole tablets 50 mg twice daily . The most common adverse reactions in the riluzole group (in at least 5% of patients and more frequently than in the placebo group) were asthenia, nausea, dizziness, decreased lung function, and abdominal pain. The most common adverse reactions leading to discontinuation in the riluzole group were
nausea, abdominal pain, constipation, and elevated ALT.
There was no difference in rates of adverse reactions leading to discontinuation in females and males. However, the incidence of dizziness was higher in females (11%) than in males (4%). The adverse reaction profile was similar in older
and younger patients. There were insufficient data to determine if there were differences in the adverse reaction profile in different races. …
Drug interactions
7.1 Agents that may Increase Riluzole Blood Concentrations
7.2 Agents that may Decrease Riluzole Plasma Concentrations
7.3 Hepatotoxic Drugs
CYP1A2 inhibitors
Co-administration of riluzole (a CYP1A substrate) with CYP1A2 inhibitors was not evaluated in a clinical trial; however, in vitro findings suggest an increase in riluzole exposure is likely. The concomitant use of strong or moderate CYP1A2 inhibitors (e.g., ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, zileuton) with riluzole may increase the risk of riluzole-associated adverse reactions .
CYP1A2 inducers
Co-administration of riluzole (a CYP1A substrate) with CYP1A2 inducers was not evaluated in a clinical trial; however, in vitro findings suggest a decrease in riluzole exposure is likely. Lower exposures may result in decreased efficacy .
Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). Riluzole-treated patients who take other hepatotoxic drugs may be at an increased risk for hepatotoxicity .
About this medicine
Riluzole is a member of the benzothiazole class. The chemical designation for riluzole is 2-amino-6-(trifluoromethoxy) benzothiazole. Its molecular formula is C8H5F3N2OS, and its molecular weight is 234.2. The chemical structure is:
Riluzole is a white to slightly yellow powder that is very soluble in dimethylformamide, dimethylsulfoxide, and methanol; freely soluble in dichloromethane; sparingly soluble in 0.1 N HCl; and very slightly soluble in water and in 0.1 N NaOH.
Each film-coated tablet for oral use contains 50 mg of riluzole and the following inactive ingredients: dibasic calcium phosphate anhydrous, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, croscarmellose sodium, hypromellose, lactose monohydrate, titanium dioxide, triacetin, citric acid monohydrate.
How it works: 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown. The clinical pharmacodynamics of riluzole has not been determined in humans. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ccead445-970c-46a1-9532-2848cc2aa3b6. Read the full official label on DailyMed.